Systemic,Psoriasis,Therapeutic health Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2

The technology behind listening devices has improved dramatically in recent years, giving new hope to those with impairment. While still far from a perfect replacement for the natural ability to hear, these devices give those with a disabili If the vagina is not offering the firm grip to your male partner, he expresses displeasure in lovemaking. You need to tighten the orifice and regain lost elasticity. You can make use of herbal remedies for loose vagina treatment naturally. H

DescriptionGBI Research, the leading business intelligence provider, has released its latest research: ‘Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth’, which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research’s team of industry experts.In 2014, the value of the Psoriasis Therapeutics Market in APAC amounted to an estimated $435m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $773m. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations. Biologics such as TNF inhibitors (adalimumab, etanercept, infliximab) and ustekinumab are largely prescribed as second-line therapy when none of the aforementioned options provide the desired results. However, during the forecast period, biologics are likely gain a significant market share due to healthcare plans in APAC and awareness regarding the effectiveness of biologics. Among the recently launched biologics, Cosentyx (secukinumab) from Novartis has shown better efficacy than Enbrel (etanercept), and is a novel molecule that targets Interluekin-17 (IL-7). Biocon India has launched Alzumab (itolizumab), which is a first-in-class novel molecule that targets CD6 protein. It is anticipated to be the leading biologic in India by the end of forecast period. Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab) are expected to lose their patent during the forecast period, but will be compensated for by biosimilar versions.Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/286550ScopeThe report analyzes treatment use patterns, market characterization, the pipeline, and key licensing and co-development deals for psoriasis in the APAC markets of China, India, Japan, and Australia.The report includes:A brief introduction to psoriasis, including pathophysiology, etiology, diagnosis, and treatment algorithmsIn-depth analysis of currently marketed drugs, including analysis of safety, efficacy, treatment patterns, and strengths/weaknesses, along with a heat map comparing them in terms of safety and efficacyA comprehensive review of the pipeline for psoriasis, including individual analysis of a number of late-stage pipeline drugs likely to enter the market during the forecast period; the pipeline is further analyzed on the basis of phase distribution, molecule type, program type, mechanism of action, and molecular targetAdditional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration, and program failure rate for each molecule typeMulti-scenario forecast data for the market to 2021, taking into account how it might be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed marketsDiscussion of the drivers of and barriers to market growthIn-depth analysis of all licensing and co-development deals that have occurred in the psoriasis market since 2006Reasons To BuyThe report will enhance your decision-making capability by allowing you to:Understand the psoriasis pipeline and the factors that indicate that it is becoming more innovativeAnalyze detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will beFollow the trends in psoriasis clinical trial size and duration in relation to industry averagesAssess the potential risk of future developmental programs for psoriasis therapeutics by mechanism of action using recorded clinical trial failure ratesAnalyze the potential growth patterns expected for the psoriasis market over the forecast periodIdentify the countries that are expected to contribute the most to this growth and devise a more effectively tailored country strategy through an understanding of key drivers and barriersAccelerate and strengthen your market position by identifying key companies for strategic partnershipsTable of Contents1 Table of Contents 61.1 List of Tables 81.2 List of Figures 82 Introduction 102.1 Symptoms 112.1.1 Skin Manifestations 112.1.2 Psychological Impact 112.2 Etiology, Co-morbidities and Risk Factors 112.2.1 Genetics 112.2.2 Psoriatic Arthritis 112.2.3 Mental Health Disorders 112.2.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 122.2.5 Infections 122.2.6 Köebner Phenomenon 122.2.7 Other Immune-Mediated Diseases 132.3 Pathophysiology 132.4 Diagnosis 132.5 Epidemiology 142.6 Treatment and Management 152.6.1 Pharmacological Therapies 162.6.2 Non-pharmacological Therapies 172.6.3 Combination and Rotational Therapies 182.6.4 Quality of Life Assessments 182.6.5 Summary 18Browse More PressRelease:http://www.marketresearchreports.biz/pressreleasesContactMr. Nachiket90 Sate Street, Suite 700Albany, NY 12207Tel: +1-518-621-2074Website: http://www.marketresearchreports.biz/E: [email protected]